Thiazole as a Promising Scaffold for the Treatment of Schistosomiasis: In Vitro and In Vivo Activity Against Different Developmental Stages of Schistosoma mansoni

Rocha, João Victor Ritinto da; França, Wilza Wanessa Melo; Machado, Arthur Lessa; Cavalcante, Lucas Andrade Oliveira; Gonçalves, Maria Tairla Viana; Aguiar, Thierry Wesley de Albuquerque; Marques, Diego Santa Clara; Nascimento, Pedro Henrique do Bomfim; Araújo, Hallysson Douglas Andrade de; Filho, Iranildo José da Cruz; Lima, Maria do Carmo Alves de; Aires, André de Lima

doi:10.3390/ph19030420

Open AccessArticle

Thiazole as a Promising Scaffold for the Treatment of Schistosomiasis: In Vitro and In Vivo Activity Against Different Developmental Stages of Schistosoma mansoni

by

João Victor Ritinto da Rocha

^1,2,

Wilza Wanessa Melo França

^1,2,*

,

Arthur Lessa Machado

²,

Lucas Andrade Oliveira Cavalcante

^1,2

,

Maria Tairla Viana Gonçalves

^1,2,

Thierry Wesley de Albuquerque Aguiar

²,

Diego Santa Clara Marques

^3,4,

Pedro Henrique do Bomfim Nascimento

⁴,

Hallysson Douglas Andrade de Araújo

^2,5

,

Iranildo José da Cruz Filho

^3,4,

Maria do Carmo Alves de Lima

⁴

and

André de Lima Aires

^1,2,3,*

¹

Centro de Ciências Médicas, Programa de Pós-Graduação em Medicina Tropical, Universidade Federal de Pernambuco, Avenida Prof. Moraes Rego, 1235, Cidade Universitária, Recife 50670-501, PE, Brazil

²

Instituto Keizo Asami (iLIKA), Universidade Federal de Pernambuco, Avenida Prof. Moraes Rego, 1235, Cidade Universitária, Recife 50670-501, PE, Brazil

³

Centro de Biociência, Programa de Pós-Graduação em Morfotecnologia, Universidade Federal de Pernambuco, Avenida Prof. Moraes Rego, 1235, Cidade Universitária, Recife 50670-501, PE, Brazil

⁴

Centro de Biociência, Departamento de Antibióticos, Universidade Federal de Pernambuco, Avenida Prof. Moraes Rego, 1235, Cidade Universitária, Recife 50670-501, PE, Brazil

⁵

Laboratório de Biotecnologia e Fármacos, Laboratório de Tecnologia de Biomateriais, Centro Acadêmico de Vitória de Santo Antão, Universidade Federal de Pernambuco, Vitória de Santo Antão 55608-680, PE, Brazil

^*

Authors to whom correspondence should be addressed.

Pharmaceuticals 2026, 19(3), 420; https://doi.org/10.3390/ph19030420

Submission received: 3 February 2026 / Revised: 1 March 2026 / Accepted: 2 March 2026 / Published: 4 March 2026

(This article belongs to the Special Issue Advances in Antiparasitic Drug Research)

Download

Browse Figures

Review Reports Versions Notes

Abstract

Background: Schistosomiasis affects more than 250 million people, and praziquantel remains the only drug available for treatment; however, its activity is restricted to adult worms. Previously, our group evaluated six thiazole derivatives (PBT1–PBT6) in vitro against adult Schistosoma mansoni, identifying PBT2, PBT5, and PBT6 as the most active compounds. The present study aimed to evaluate the in vitro activity of PBT2, PBT5, and PBT6 against schistosomula and juvenile worms, as well as their in vivo efficacy against adult S. mansoni. Methods: Mechanically transformed schistosomula and juvenile worms recovered from mice (21 days post-infection) were incubated with the compounds (12.5–200 μM). Cytotoxicity was assessed using murine splenocytes and peritoneal macrophages exposed to the same concentration range. For in vivo evaluation, infected mice were orally treated with compounds (50, 100, or 200 mg/kg) for five consecutive days. Results: All compounds induced 100% mortality in schistosomula and juvenile worms within 3 h of exposure at 100 and 200 μM. Parasite cell viability was markedly reduced (>90%) at concentrations between 50 and 200 μM. The LC₅₀ values ranged from 15.3 to 30.9 μM for schistosomula and from 27.8 to 34.9 μM for juvenile worms, with low cytotoxicity observed in mammalian cells (CC₅₀ ≥ 193.9 μM). In vivo treatment resulted in significant reductions in fecal egg counts (~80% at 200 mg/kg), total worm burden (~60%), and egg loads in liver and intestinal tissues, in addition to an increased proportion of dead eggs in the intestine. Conclusions: The evaluated thiazole derivatives demonstrated potent in vitro activity against immature stages of S. mansoni and significant in vivo efficacy against adult parasites, accompanied by favorable changes in key parasitological parameters. These findings reinforce the potential of thiazole-based compounds as promising multistage schistosomicidal candidates.

Keywords:

antiparasitic; schistosomicide; immature stages; thiazole; selectivity index

Graphical Abstract

1. Introduction

Schistosomiasis is a helminthic disease caused by blood flukes of the genus Schistosoma spp. and affects more than 250 million people across 78 countries and territories worldwide, placing nearly one billion individuals at risk of infection. The disease is responsible for more than 300,000 deaths every year [1,2]. In 2021, schistosomiasis accounted for approximately 1.8 million disability-adjusted life years (DALYs), and its persistence, reflected by high prevalence and incidence rates in endemic regions, continues to represent a major public health challenge despite ongoing control efforts. Beyond the substantial burden on healthcare and security systems, schistosomiasis causes profound socioeconomic and emotional losses [2,3,4,5]. The distribution of schistosomiasis cases and pathogenicity varies according to the Schistosoma species, since each one has biological particularities, different intermediate hosts (snails), and distinct epidemiological patterns [1]. Depending on the species, schistosomiasis affects the hepatosplenic and gastrointestinal systems or the urogenital system [1,2].

S. haematobium inhabits the venous plexus of the bladder and causes the urogenital form of schistosomiasis, which has the greatest public health impact [1,2,5,6]. According to the World Health Organization, it is the most pathogenic species, accounting for approximately 60–70% of cases worldwide, mainly in Africa and the Middle East [5,6,7]. The infection is characterized by hematuria, bladder fibrosis, lesions of the ureters and kidneys, squamous cell carcinoma of the bladder, and genital manifestations, including testicular pain and hematospermia in men, and abdominal and pelvic pain, dyspareunia, ectopic pregnancy, and infertility in women; it is also associated with increased HIV transmission in co-endemic areas [1,5,6,7]. S. mansoni, S. japonicum, and S. intercalatum are the species responsible for the hepatosplenic and gastrointestinal forms of schistosomiasis [1,6,7]. S. mansoni inhabits the hepatic portal system and mesenteric veins and accounts for approximately 30–35% of global schistosomiasis cases, particularly in Africa and South America; it is also the only species endemic in Brazil [4,5,6,7]. The infection typically manifests with abdominal pain, diarrhea, hematochezia, and Katayama syndrome during the acute phase. In chronic and advanced stages, it can progress to hepatosplenomegaly, periportal and intestinal fibrosis, portal hypertension, and ascites [1,2,3].

Despite advances in scientific knowledge, no licensed vaccine for schistosomiasis is currently available, and its clinical development remains uncertain [8]. Consequently, disease control relies exclusively on praziquantel (PZQ), a pyrazylisoquinoline derivative that has been used for more than six decades [5,9]. However, PZQ does not prevent reinfection and shows limited efficacy against early developmental stages, such as schistosomula and juvenile worms, at recommended doses, being predominantly active against adult worms [4,8,10].

The lack of alternative therapeutic options reflects stagnation in pharmacological development, largely due to the high cure rates achieved by PZQ against adult worms, although it is crucial in preventing thousands of deaths. Nevertheless, Amorim et al. [11] warn that reduced PZQ efficacy could lead to a setback in schistosomiasis control. For this reason, the search for new therapeutic alternatives is urgent. Moreover, emerging evidence of Schistosoma spp. strains resistant or tolerant to PZQ has been reported [8,9]. In 2021, only 30% of infected individuals had access to PZQ treatment, underscoring its limited availability relative to global demand and reinforcing the urgent need for investment in research and development of new schistosomiasis drugs [2].

In this context, the thiazole nucleus, a heterocycle scaffold containing sulfur and nitrogen atoms, has emerged as a versatile and promising framework in medicinal chemistry for the synthesis of active molecules [12,13,14]. Thiazole derivatives are present in several clinically approved drugs due to their multi-target pharmacophoric groups, such as antimicrobials (sulfathiazole), antifungals (abafungin), antivirals (ritonavir), and antiparasitics (thiabendazole and nitazoxanide) [15,16,17,18]. Thiazole compounds have also been used in preclinical in vitro and in vivo screening of new drugs [12,14] as antioxidants [19], antitumor [20], antibacterial and antibiofilm agents [21], and against Mycobacterium tuberculosis [22]. Thiazole compounds have demonstrated in vitro and in vivo activity in antiparasitic studies against Trypanosoma cruzi [13,23,24], Toxoplasma gondii [25,26], Plasmodium spp. [27], Leishmania spp. [13], and Giardia intestinalis, Trichomonas vaginalis, Leishmania amazonensis, and T. cruzi [28]. In a review, Vajedpour et al. [29] described the promising activity of thiazoles as anthelmintics against nematodes, cestodes, and platyhelminths.

Previously, our group demonstrated that novel thiazole derivatives (PBT2, PBT5, and PBT6) exhibit potent in vitro schistosomicidal activity against adult S. mansoni worm pairs, promoting mortality, impaired motility, and reduced cell viability, along with favorable in silico ADMET profiles [10]. The present study aimed to extend the preclinical evaluation of these compounds by investigating their in vitro activity against schistosomula and juvenile worms using mortality, motility, and cell viability scores, and their in vivo efficacy against adult S. mansoni, focusing on parasitological load, tissue egg burden in liver and intestinal tissues, and oviposition patterns.

2. Results and Discussion

2.1. Thiazole Compounds Induce Mortality, Impair Motility, and Reduce Cell Viability in Schistosomula and Juvenile Worms of Schistosoma mansoni

The in vitro susceptibility of S. mansoni schistosomula and juvenile worms to PBT2, PBT5, and PBT6 is summarized in Table 1 and Table 2, respectively. At all evaluated time points (3, 6, 12, and 24 h), schistosomula and juvenile worms from control groups 1 and 2 exhibited typical motility patterns, characterized by coordinated movements along the body, peristalsis of internal organs, sucker adhesion to the culture plate surface, and preservation of color and tegument integrity, corresponding to score 3 (Table 1 and Table 2). These observations are consistent with those previously described in studies evaluating in vitro screening of schistosomicidal compounds [10,30,31].

All three compounds induced rapid and pronounced schistosomicidal effects. Complete mortality (score 0) of schistosomula and juvenile worms was observed as early as 3 h post-exposure at concentrations of 200 and 100 μM, characterized by the absence of body motility and internal organ peristalsis. After 6 h, PBT2 and PBT6 (50 μM) induced 82.9% and 100% mortality in schistosomula, respectively, whereas PBT5 at the same concentration promoted marked motility reduction to the anterior and/or posterior extremities in 100% of schistosomula (score 1.5).

After 12 h of exposure, PBT2 and PBT5 at 50 μM resulted in complete schistosomula mortality, while PBT6 achieved the same effect at both 50 μM and 25 μM. After 24 h, PBT2 induced 100% mortality at 25 μM, whereas at 25 and 12.5 μM caused sublethal effects, reducing motility to score 1.5. Against juvenile worms, PBT6 at 50 μM caused complete mortality within 3 h, while 25 μM reduced motility to score 1 after 24 h. PBT2 and PBT5 at 50 μM reduced juvenile worm motility to score 1 in 100% and 66.3% of worms, respectively, within 12 h, with total mortality observed at 24 h.

In contrast, PZQ did not induce mortality in schistosomula or juvenile worms and resulted in reduced motility scores of 1.5 and 1, respectively. These findings corroborate previous reports demonstrating the lack of PZQ activity against immature stages of S. mansoni, which limits its efficacy primarily to adult worms [8,9,32]. It is serious that S. mansoni in immature stages is refractory to PZQ; in addition to the selection of strains under drug pressure, the parasite undergoes adaptive mechanisms to survive, migrate, and complete its development into adult worms, establishing pathogenicity and the continuity of its biological cycle [4,9].

Previous work by Silva et al. [10] demonstrated that PBT2, PBT5, and PBT6 exhibited schistosomicidal activity against adult S. mansoni worm pairs, although higher concentrations and longer exposure times were required compared to those observed in the present study. In this study, PBT2 and PBT5 caused 100% mortality at 200 µM within 3 h and at 100 µM within 6 h, while PBT6 at 200 µM promoted 100% mortality only after 12 h and 81.25% at 100 µM within 24 h. In our study, PBT2, PBT5, and PBT6 exhibited activity against schistosomula and juvenile worms at 200 μM and 100 μM, achieving mortality within 3 h, while the same effect was observed at 50 μM and 25 μM after 24 h. Furthermore, we observed a marked reduction in motility at 12.5 μM within 24 h, indicating a sublethal effect and suggesting sustained antiparasitic pressure even at low concentrations.

In vitro studies on synthetic compounds targeting immature stages of S. mansoni remain limited. Thiosemicarbazone JF31 and thiazolidinone JF43 at 200 μM promoted 100% mortality against adult worm pairs and juvenile worms after 24 h and 48 h, respectively [30]. Aryl-thiazoles NJ05 and NJ07 at 50 μM caused 75% and 50% mortality against schistosomula, respectively, in addition to approximately 50% mortality against adult worm pairs within 120 h post-exposure [32]. Santiago et al. [33], when evaluating hydrazone, thiosemicarbazone, phthalimide, and thiazole compounds against adult S. mansoni worm pairs, reported that activity was exclusive to the thiazoles LpQM-43, LpQM-45, LpQM-47, and LpQM-14. LpQM-45 and LpQM-14 caused 100% mortality at 100 and 80 μg/mL within 144 and 168 h, respectively, while LpQM-43 and LpQM-47 caused 67% and 95% mortality, respectively, in 192 h at 100 μg/mL. Compared to other thiazole-based compounds reported in the literature, PBT2, PBT5, and PBT6 exhibited superior potency, inducing rapid lethality at substantially lower concentrations and shorter incubation periods. These findings highlight the therapeutic relevance of thiazole scaffolds as promising candidates for multistage schistosomicidal therapy.

2.2. Thiazole Compounds Significantly Reduce Cell Viability of Schistosomula and Juvenile Worms

The effects of PBT2, PBT5, and PBT6 on parasite cell viability are shown in Figure 1A,B. All compounds induced a concentration-dependent reduction in cell viability in both schistosomula and juvenile worms. In schistosomula, all compounds significantly reduced cell viability (p < 0.001), except for PBT5 at 6.25 µM. At concentrations 200, 100, and 50 μM, cell viability was reduced by more than 90% compared to the negative control (C2, p < 0.001; Figure 1A). At 25 μM, PBT2 and PBT5 reduced cell viability by 43.7% and 36.0%, respectively, whereas PBT6 exerted a more pronounced effect, reducing viability by 71.0% at 25 μM and 38.5% at 12.5 μM (p < 0.001).

In juvenile worms, all compounds significantly reduced cell viability (p < 0.001) at concentrations ranging from 12.5 and 200 µM, with reductions exceeding 80% at concentrations 50 µM, 100 µM, and 200 µM compared to the control (C2). At lower concentrations, PBT2 reduced cell viability similarly to PZQ in schistosomula; a similar effect was observed in young worms at concentrations of 25 μM and 12.5 μM treated with PBT2 and PBT5. Parasites exposed to PZQ exhibited viability values of 45.2% in schistosomula and 83.2% in juvenile worms, consistent with its limited activity against immature stages (Figure 1A,B). Results are consistent with studies by Araújo et al. [34], Talaam et al. [35], and Silva et al. [31] which highlight that PZQ has a low effect on the cell viability of the immature stage of S. mansoni. Against adult worm pairs, Silva et al. [10] reported that PBT2, PBT5, and PBT6 promoted a significant reduction (p < 0.001) in cell viability, a similar reduction to PZQ, at concentrations of 200 and 100 μM after 120 h.

Triazole compounds are known to interact with numerous cells in different biological targets, reducing or preventing biological activity in the target organism. The tegument of S. mansoni is rich in mitochondria and plays a central role in parasite energy metabolism, proliferation, tissue repair, and selective drug uptake [35,36]. Disruption of mitochondrial function is therefore a critical target for schistosomicidal compounds [32,36,37,38,39,40]. The pronounced reduction in parasite viability observed in this study suggests that PBT2, PBT5, and PBT6 induce mitochondrial dysfunction, surpassing the effects of PZQ under the evaluated conditions. Thiazole compounds exhibit schistosomicidal activity through multimodal mechanisms involving structural and metabolic alterations [41,42]. Our results indicate that the mitochondrial dysfunction induced by the compounds arises from their interaction with nucleic acid-rich organelles, thereby triggering cytotoxic effects in the worms, a mechanism previously reported for other schistosomicidal candidates [10,11,29,30,32,33,34,35,39,42].

2.3. Lethal Concentration, Cytotoxicity, and Selectivity Index

PBT2, PBT5, and PBT6 exhibited LC₅₀ values of 27.84 ± 3.4, 30.89 ± 2.8, and 15.33 ± 2.2 μM against schistosomula, and 32.85 ± 3.8, 34.92 ± 3.2, and 27.76 ± 2.5 μM against juvenile worms, respectively (Table 3). According to established criteria [37,38], all compounds were classified as active (LC₅₀ < 50 μM). These LC₅₀ values were notably lower than those previously reported by Silva et al. [10] for adult worm pairs, indicating enhanced efficacy against immature stages. Similar results were obtained by Oliveira et al. [39], Pereira et al. [32], and Oliveira Barbosa et al. [40] regarding the viability of S. mansoni exposed to different thiazole compounds. Series of phthalimido-thiazole compounds against S. mansoni adult worms exhibited LC₅₀ values ranging from 138.09 to 302.97 μM [39] and 50.6 to 305.6 μM [40]. Compounds with improved lipophilicity, stability and permeability ensure better access to the target, and the interference in more than one biological pathway of the parasite and the reduction in its metabolic compensation capacity result in a lower LC₅₀ [41], as demonstrated by LC₅₀ values of 49.36–114.18 μM [42]. Thiosemicarbazone and thiazole compounds promoted LC₅₀ values ranging from 19.97 to 84.13 μM against S. mansoni pairs of adult worms [33]. The identification of active compounds in multiple stages of S. mansoni may overcome the limitation of PZQ against immature forms and expand the effectiveness of chemotherapy in endemic areas [8].

The absence or low cytotoxicity in mammalian cells and high parasite selectivity are essential requirements for schistosomicidal candidates [8,10,42]. In the studies by Silva et al. [10], using immortalized cell lines, PBT2, PBT5, and PBT6 showed low cytotoxicity with CC₅₀ ranging from 107.05 μM to >400 μM in RAW 264.7 macrophages, from 140.01 μM to >400 μM in fibroblasts, from 161.88 μM to >400 μM in Vero cells, and >400 μM for HepG2 cells. Furthermore, the three compounds evaluated did not promote hemolysis. In contrast to the absence of cytotoxicity of PBT2, PBT5, and PBT6 in HepG2 cells (>400 μM), thiazole series exhibited substantially lower CC₅₀ in this cell line, ranging from 6.78 to 40.33 μM [43] and from 13.92 to 117.78 μM [44].

CC₅₀ values for thiazoles are predominantly concentrated in immortalized or tumor cell lines, being limited in primary cells. Primary cells preserve characteristics and functions more similar to in vivo tissue than immortalized cell lines, improving the prediction of drug toxicity and safety in preclinical evaluations for subsequent in vivo trials [45]. Cytotoxicity assays using primary murine splenocytes and peritoneal macrophages revealed low toxicity for all compounds, with CC₅₀ values ranging from 193.9 to 297.3 μM in splenocytes and ≥277.5 μM in macrophages (Table 3). In contrast, PZQ exhibited marked cytotoxicity in splenocytes (CC₅₀ = 3.2 ± 0.8 μM). None of the compounds met the criteria for cytotoxicity (CC₅₀ > 100 μM), indicating a favorable safety profile [46].

The selectivity index (SI) values ranged from 5.84 in juvenile worms to greater than 26 in schistosomula. High selectivity indices are indicative of a favorable safety profile and therapeutic window and reinforce the potential of these thiazole derivatives as promising schistosomicidal candidates [38]. PBT6 promoted lower CL₅₀ and higher CC₅₀ compared to the other compounds, resulting in a higher SI, indicating better antiparasitic activity associated with lower cytotoxicity. The 4-phenyl-2-aminothiazole GPQF-108 presented an LC₅₀ of 29.44 μM against adult worms and CC₅₀ of 179.44 in Vero cells, resulting in an SI of 6.09 [11]. Phthalimido-thiazoles showed low cytotoxicity on Vero cells (CC50 of 112.9 to 1582.9 μM) [47] and on macrophage J774 (CC50 of 125.6 μM to 1582.9 μM) [40]. The diversity of these results shows that thiazoles stand out as versatile scaffolds whose structural variations modulate schistosomicidal activity and demonstrate their potential as a promising platform for the rational development of new schistosomicides [32].

2.4. The Compounds Reduce Fecal Egg Output, Adult Worm Burden, Tissue Egg Deposition, and Alter the Oviposition Pattern in Mice Infected with Schistosoma mansoni

The Kato–Katz technique is widely used for the diagnosis of schistosomiasis and for evaluating parasitological cure, as it enables estimation of infection intensity and classification of endemic areas for mass drug administration [48]. Prior to treatment, significant differences were observed among the experimental groups regarding the number of eggs per gram of feces (EPG) (p > 0.05), with values ranging from 322.7 ± 53.8 to 357.3 ± 50.1, indicating homogeneous infection levels across groups.

Following treatment, except for the 50 mg/kg dose of PBT5, all compounds induced a significant reduction in EPG values (p < 0.001), reaching approximately 80% reduction at the 200 mg/kg dose (Figure 2). These findings indicate a strong potential of the compounds to reduce environmental contamination and interrupt the biological cycle of S. mansoni [1,48,49]. PZQ reduced EPG values by 95.1% compared with the control group, consistent with previous studies [50,51,52]. Amorim et al. [11] demonstrated that among 17 4-Phenyl-2-Aminothiazole derivatives, GPQF-108 promoted a 56% reduction in fecal egg counts following a single oral dose of 400 mg/kg. A significant decrease in oviposition was observed by Pereira et al. [32].

All three compounds reduced total worm burden, female worm counts, and egg deposition in hepatic and intestinal tissues in a dose-dependent manner (Table 4). Treatment with 200 mg/kg resulted in an approximately 60% reduction (p < 0.001) in both total and female worm burdens, suggesting comparable activity against male and female parasites. These findings contrast with in vitro and in vivo studies reporting greater susceptibility of male worms, whether paired and unpaired [53,54]. PZQ reduced total worm burden by 99%, corroborating results reported by Aires et al. [51]. Except for the 50 mg/kg dose of PBT5, all doses of PBT2, PBT5, and PBT6 significantly reduced egg counts in liver and intestinal tissue (p < 0.001), with reductions ranging from 34.41 to 59.41% and 29.2–61.5%, respectively, compared with the control group (Table 4).

Understanding parasite biology is essential for the development of new antischistosomal drugs, and analysis of the oviposition pattern through oogram evaluation represents a key parasitological parameter [55]. The oogram is considered altered when one or more developmental stages are absent and modified when significant changes occur in the relative proportions of egg stages. In intestinal tissue samples from control groups 1 and 2, S. mansoni eggs were observed at all developmental stages (immature [I–IV], mature, and dead), with a percentage distribution consistent with those previously reported in the literature [31], indicating preserved reproductive dynamics of the worm pairs.

In contrast, treatment with PBT2, PBT5, and PBT6 induced significant and dose-dependent alterations in the oviposition pattern, characterized primarily by a reduction in immature eggs and a marked increase in dead eggs (p < 0.001), as shown in Table 5. The 200 mg/kg dose yielded the highest proportions of dead eggs, reaching 56.2 ± 7.08%, 53.2 ± 2.16%, and 59.4 ± 6.6% for PBT2, PBT5, and PBT6, respectively, with statistically significant differences compared with the 100 and 50 mg/kg doses. These findings demonstrate that higher compounds doses potentiate their effects on the oviposition pattern of S. mansoni. Treatment with PZQ resulted in 95.8% egg mortality in intestinal tissue, a significant reduction in mature eggs (4.2%), and the complete absence of immature eggs.

The activity of PBT compounds on the oogram is particularly relevant, as it indicates schistosomicidal effects on egg viability within intestinal tissue. Reductions in immature and mature eggs may be partially attributed to decreased fecundity of surviving worm pairs and/or delayed embryonic development following oviposition. Conversely, the increase in dead eggs suggests a direct ovicidal effect, comparable to that observed with PZQ.

Amorim et al. [11] reported that GPQF-108, administered as a single oral dose of 400 mg/kg, reduced total S. mansoni worm burden by 53.74% (p < 0.01) and selectively modifying the oogram by reducing immature eggs (38.72%, p < 0.05), without affecting mature or dead egg viability. From nine phthalimido-thiazole compounds, only compound 2m demonstrated biosafety and schistosomicidal activity in vitro against adult S. mansoni [40]. In vivo, compound 2m reduced worm burden by 94.6% following five consecutive days of treatment at 200 mg/kg/day and by 75.6% after a single oral dose of 400 mg/kg. However, neither regimen produced significant reductions in hepatic and intestinal egg loads, nor did they modify the oviposition pattern. Among six phthalimido-thiazoles (2b–2j), only compound 2i exhibited in vitro activity after 144 h and advanced to in vivo evaluation in S. mansoni-infected mice. Treatment with 2i at 400 mg/kg for five consecutive days significantly reduced worm burden by 81.25% and 69.2% (p < 0.05) following oral and intraperitoneal administration, respectively, with no significant differences between routes [42]. In that study, compound 2i also reduced intestinal egg load (~45%, p < 0.05), without affecting hepatic egg counts, and altered the oogram by decreasing mature (23.7%) and immature (22.5%) eggs while increasing dead eggs (53.8%).

Thus far, the mechanism by which thiazole compounds act on S. mansoni has not been fully elucidated, possibly due to their structural diversity and the versatility of the thiazole nucleus [30,32,33,56]. In the present study, although PBT2, PBT5, and PBT6 exhibited similar schistosomicidal activity in vitro and in vivo, these compounds differ in terms of the substituents on the thiazole ring (–NO₂, –Cl, –F, and –H; Figure 3). The biological activity of nitroaromatic compounds involves the reductive biotransformation of the nitro group, generating reactive intermediates such as nitro, nitroso, and hydroxylamine radicals, through the generation of reactive oxygen species and depletion of cellular antioxidant systems. These metabolites can react with iron or thiol groups in proteins and other macromolecules, leading to the inactivation of enzymes essential for mitochondrial respiration and DNA replication, promoting the death of the parasite [32,56]. This mechanism is consistent with that described for clinically used nitro-heterocyclic drugs, such as metronidazole, tinidazole, secnidazole, benznidazole, and nifurtimox, whose antiparasitic efficacy critically depends on the reduction in the nitro group and the subsequent formation of cytotoxic metabolites [56,57].

The introduction of halogens into bioactive scaffolds is a well-established strategy in medicinal chemistry to enhance lipophilicity. Halogenated substituents such as chlorine and fluorine can increase passive permeability across biological membranes, as well as promote intermolecular interactions, including hydrophobic contacts and halogen-acceptor bonds (halogen bonding), increasing affinity and selectivity for protein targets and the bioavailability [58,59]. S. mansoni possesses a tegumental surface rich in lipids; therefore, increased lipophilicity may facilitate compound permeation through the tegument, enhancing access to intracellular targets. Modulation of tegumental permeability represents a relevant pharmacological mechanism, as exemplified by PZQ, which increases Ca²⁺ permeability in S. mansoni. Although it has been used since the 1970s and investigated in numerous studies, the exact mechanism of action of PZQ has not yet been fully elucidated. However, it is known that PZQ acts on Ca²⁺ homeostasis in the integument and is responsible for causing spasms, damage to the integument, and muscular paralysis, leading to the death of adult worms [4,5,9].

No significant differences were observed between control groups 1 and 2 (C1 and C2; p > 0.05) regarding fecal egg counts (Figure 4), worm burden (total and female), hepatic and intestinal egg loads (Table 4), or oviposition pattern (Table 5). These findings confirm that Cremophor^® (1%), used as an excipient, exhibited no schistosomicidal activity, supporting its use solely as a solvent [40,54,60] and allowing the observed effects to be attributed exclusively to the evaluated compounds.

3. Materials and Methods

3.1. Reagents and Solvents

The following commercial reagents and solvents were used: 2-bromoacetophenone (Merck, Rahway, NJ, USA, CAS 70-11-1), 2-bromo-4-nitroacetophenone (Merck, Rahway, NJ, USA, CAS 2227-64-7), 2-bromo-4-chloroacetophenone (Merck, Rahway, NJ, USA, CAS 536-38-9), 2,4-dibromoacetophenone, 2-chloro-4-fluoroacetophenone (Merck, Rahway, NJ, USA, CAS 456-04-2), 4-nitrophenyl isothiocyanate (Merck, Rahway, NJ, USA, CAS 2131-61-5), 4-chlorophenyl isothiocyanate (Merck, Rahway, NJ, USA, CAS 2131-55-7), 4-hydroxybenzaldehyde (Merck, Rahway, NJ, USA, CAS 123-08-0), hydrazine solution (Merck, Rahway, NJ, USA, CAS 302-01-2). Sodium chloride (Merck, Rahway, NJ, USA, CAS 7647-14-5), praziquantel (Merck, Rahway, NJ, USA, CAS 55268-74-1) and Cremophor^® (Sigma, Ronkonkoma, NY, USA, C5135-500G). All analytical grade and cell culture reagents were obtained from Sigma Chemical Co., St. Louis, MO, USA.

3.2. Synthesis of Thiazole Compounds

Thiazole derivates were synthesized and supplied by the Laboratory of Chemistry and Therapeutic Innovation (LQIT) of the Department of Antibiotics at the UFPE, in Recife, Pernambuco, Brazil. Compound synthesis was performed in three stages following previously described methodologies [61,62,63] with minor modifications. In the first stage, thiosemicarbazides were prepared through a nucleophilic addition reaction between hydrazine and either 4-nitrophenyl isothiocyanate or 4-chlorophenyl isothiocyanate in dichloromethane at room temperature under magnetic stirring for 1 h. In the second stage, thiosemicarbazones were synthesized by reacting the thiosemicarbazides with 4-hydroxybenzaldehyde in absolute ethanol in the presence of acetic acid as a catalyst, under magnetic stirring at room temperature. In the third step, thiazole derivatives were obtained through cyclization of thiosemicarbazones with substituted acetophenones bearing phenyl, 4-chlorophenyl, or 4-nitrophenyl groups, yielding the compounds PBT2, PBT5, and PBT6. The synthetic route is illustrated in Figure 3.

3.3. Ethics Committee and Animals

All experimental procedures involving animals were conducted in accordance with the guidelines of the National Council for the Control of Animal Experimentation (CONCEA) and approved by the Ethics Committee on Animal Experimentation (CEUA) of the Center for Biosciences of UFPE, Brazil, (process number 0085/2022 and 0029/2025). Animal studies were reported in accordance with the guidelines “Animal research: reporting of in vivo experiments” (ARRIVE). Male BALB/c mice (8 weeks old, ~25 ± 2 g) and female Swiss Webster mice (35 days old, ~30 ± 2 g) were obtained from and maintained at the animal facility of the Keizo Asami Institute of UFPE (iLIKA-UFPE, Recife, Brazil) under standardized conditions (23 ± 2 °C, 40–50% relative humidity, 12 h light/dark cycle), with free access to water and Labina^® chow. S. mansoni (BH strain, Belo Horizonte, Minas Gerais, Brazil) has been maintained through successive passages in Biomphalaria glabrata snails (SLM strain, São Lourenço da Mata, Pernambuco, Brasil) and Swiss Webster mice at the Academic Area of Tropical Medicine and iLIKA at UFPE. Snails were housed in plastic tanks (50 × 23 × 17 cm) containing filtered and dechlorinated water (20 L), renewed weekly, and fed daily with fresh lettuce leaves (Lactuca sativa L.), under controlled temperature (25 ± 2 °C) and a 12 h light/dark photoperiod.

3.4. Infection of Biomphalaria glabrata and Collection of S. mansoni Cercariae

Schistosoma mansoni eggs were obtained from the feces of experimentally infected mice using the spontaneous sedimentation technique [64]. After repeated washings, the sediment was distributed into Petri dishes and exposed to artificial light (60 W, Lightex, model A5570, Sofia, Bulgaria) to induce miracidia hatching. Using a stereomicroscope, snails were individually infected with five miracidia in 24-well culture plates (TPP-Techno Plastic Products, Trasadingen, Switzerland) and exposed to artificial light for 4 h. Subsequently, snails were transferred to plastic tanks in a light-protected environment. After 35 days post-infection, snails (n = 80) were exposed to artificial light (60 W) for 2 h to stimulate cercarial shedding.

3.5. In Vitro Assay Against S. mansoni Schistosomula

Cercariae of S. mansoni were mechanically transformed into schistosomula as previously described (Figure 4A) [34,65]. Schistosomula were washed four times in RPMI 1640 medium (Sigma Aldrich, St. Louis, MO, USA) supplemented (20 mM HEPES, 100 μg/mL penicillin, 100 μg/mL streptomycin and 10% fetal bovine serum) and incubated at 37 °C in a humidified atmosphere containing 5% CO₂ for 5 h to allow adaptation.

Subsequently, 70 schistosomula were distributed per well in 24-well culture plates and exposed to PBT2, PBT5, or PBT6 diluted in 1% Dimethyl sulfoxide (DMSO) to obtain final concentrations of 200, 100, 50, 25, 12.5, and 6.25 μM (final volume: 2 mL/well). Under the same experimental conditions, negative controls consisting of parasites incubated in supplemented RPMI 1640 alone or RPMI 1640 containing 1% DMSOs schistosomula were incubated only with supplemented RPMI 1640 medium or RPMI. The positive control group was treated with PZQ (10 μM). Two independent experiments were performed in duplicate.

3.6. In Vitro Assay Against Juvenile S. mansoni Worms

Five mice were infected caudally with 3000 cercariae and euthanized by cervical dislocation on day 21 post-infection for aseptic recovery of juvenile worms through perfusion of the portal-hepatic system with sterile saline solution (Figure 4B) (0.9% w/v NaCl) [66]. Recovered worms were transferred to Petri dishes containing supplemented RPMI 1640 medium, washed four times, and incubated (5% CO₂ at 37 °C) for 2 h to allow adaptation (Figure 4C).

Juvenile worms (n = 30) were distributed into 24-well culture plates and exposed to PBT2, PBT5, or PBT6 diluted in 1% DMSO to final concentrations of 200, 100, 50, 25, 12.5, and 6.25 μM (final volume: 2 mL/well). Under the same experimental conditions, negative control groups consisted of juvenile worms incubated in supplemented RPMI 1640 alone or supplemented RPMI 1640 containing 1% DMSO. The positive control group was treated with 10 μM of PZQ. Experiments were performed in quadruplicate and repeated independently twice, totaling 120 juvenile worms per concentration.

3.7. In Vitro Schistosomicidal Criteria Against Schistosomula and Juvenile Worms

3.7.1. Motility and Survival

Alterations in motility and survival of schistosomula and juvenile worms were evaluated using an inverted microscope (LEICA DM IL Wetzlar, Germany) at 3, 6, 12, and 24 h post-exposure (Figure 4D). Schistosomula motility and survival were scored according to Araújo et al. [34] using a three-point scale: score 3 indicated typical movements along the body, internal organs peristalsis, sucker adhesion, and preserved color and tegument; score 1.5 indicated reduced body motility or movement restricted to extremities with absence of sucker adhesion; score 0 indicated complete absence of movements with or without tegumental alterations.

Juvenile worms were classified using a four-point scale according to Araújo et al. [34] as follows: score 3 indicated typical movements along the body, internal organs peristalsis with sucker adhesion; score 2 indicated reduced motility and peristalsis; score 1 indicated movement restricted to posterior and/or anterior extremities; and score 0 indicated complete absence of movement with or without tegumental alterations. Mortality was defined as score 0 when no movement was observed within a 2 min observation period.

3.7.2. Cell Viability Assay

Cell viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Figure 4E) (Sigma-Aldrich, St. Louis, MO, USA), as described previously [34,67,68]. After the final observation time, culture medium was aspirated from the well, and parasites were washed with sterile saline solution (0.9% w/v NaCl). Subsequently, 20 schistosomula or six juvenile worms were transferred to 96-well plates containing 100 μL of MTT solution (5 mg/mL in PBS) per well and incubated for 30 min at 37 °C in the absence of light.

The MTT solution was then replaced with 200 μL of DMSO, and plates were agitated for 1 h at room temperature to solubilize the formazan crystals. Absorbance was measured at 550 nm using a microplate reader (M680, Bio Rad Laboratories, Inc., Hercules, CA, USA). MTT yellow is reduced to formazan purple by a variety of mitochondrial and cytosolic enzymes that are functional in viable cells. Worms from positive and negative control groups were subjected to the same procedure. Assays were performed in sextuplicate in two independent experiments, and results are expressed as mean ± standard deviation (SD) of percentage cell viability worms. The lethal concentration for 50% of parasites (LC₅₀) was calculated by nonlinear regression analysis of dose–response curves using GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA).

3.8. Cytotoxicity Assay in Murine Peritoneal Macrophages and Splenocytes

Five male BALB/c mice (8 weeks old, ~25 ± 2 g) were used for the collection of perito-neal macrophages and splenocytes, as described previously [69,70,71]. Peritoneal macrophages were collected by peritoneal lavage using 5 mL of RPMI 1640. Splenocytes were obtained from aseptically removed spleens, which were mechanically dissociated in RPMI 1640 medium, followed by erythrocyte lysis with sterile distilled water.

Cells were centrifuged, resuspended in supplemented RPMI 1640 medium (10% FBS, 1% antibiotics (streptomycin + penicillin)), and counted using a Neubauer chamber (Biocentrix, São Paulo, Brazil) with trypan blue exclusion. Cells were seeded in 96-well plates at a density of 1 × 10⁶ cells/well and incubated (37 °C, 5% CO₂). After 24 h, culture medium was replaced with fresh medium containing PBT2, PBT5, or PBT6 at concentrations of 6.25–400 μM solubilized in 1% DMSO. The cells were incubated for an additional 48 h at 37 °C in 5% CO₂.

After incubation, cells were washed and incubated in fresh culture medium without phenol red containing MTT (5 mg/mL) to a final volume of 200 μL/well for 3 h at 37 °C in the absence of light. The culture medium with MTT was then replaced with DMSO (100 μL/well) to solubilize the formazan derived from MTT reduction, and absorbance was measured spectrophotometrically at 540 nm. Control groups consisted of cells exposed only to supplemented RMPI 1640, supplemented RPMI 1640 with 1% DMSO, or 10 μL of PZQ. The cell viability of each concentration was calculated from the absorbances obtained by reading the plate, using the following equation:

V i a b i l i t y % = \frac{A b s o r b a n c e (t r e a t e d c e l l s) - (A b s o r b a n c e b l a n k)}{A b s o r b a n c e (N e g a t i v e c o n t r o l) - (A b s o r b a n c e b l a n k)} \times 100

Cytotoxic concentration values reducing cell viability by 50% (CC₅₀) were calculated by nonlinear dose–response regression in a 95% confidence interval using GraphPad Prism 5.0 software.

3.9. In Vitro Selectivity Index

The selectivity index (SI) was calculated by the ratio between the cytotoxicity in mammalian cells (CC₅₀) and antiparasitic activity (LC₅₀) against schistosomula and juvenile worms, as previously described [38].

3.10. Experimental Infection and Therapeutic Protocol

A total of 120 mice were anesthetized (ketamine-xylazine (100 mg/kg + 15 mg/kg)) and percutaneously infected with 80 S. mansoni cercariae (Figure 5A,B), according to Olivier and Stirewalt [68]. Animals were randomly distributed into 12 experimental groups (n = 10/group) according to the therapeutic protocol, namely

Control 1 = sterile saline solution;
Control 2 = 1% Cremophor^® in sterile saline solution;
PZQ = 50 mg/kg;
PBT2 = 200 mg/kg, 100 mg/kg or 50 mg/kg;
PBT5 = 200 mg/kg, 100 mg/kg or 50 mg/kg;
PBT6 = 200 mg/kg, 100 mg/kg or 50 mg/kg.

PZQ and the compounds were solubilized in 1% Cremophor^® in sterile saline solution (0.9% w/v NaCl). A dose of 50 mg/kg of PZQ was adopted according to Aires et al. [63], while the doses of the compounds were chosen based on in silico pharmacokinetic and pharmacodynamic prediction [10] and on the evaluation of acute oral toxicity and in vivo schistosomicidal activity of thiazole compounds [40]. Treatments were carried out for five consecutive days starting on the 45th day of infection. The animals were fasted for 60 min, and the treatment was performed via esophageal gavage with a final volume of 300 µL (Figure 5C). The Control 1 and Control 2 groups were maintained under the same rearing and handling conditions. All animals were euthanized on day 55 post-infection by cervical displacement for parasitological analysis.

3.11. In Vivo Parasitological Parameters

3.11.1. Adult Worm Recovery

Adult worms were recovered by perfusion of the portal-hepatic system and mesenteric vessels with sterile saline solution (0.9% w/v NaCl) and counted using a stereomicroscope. Worms were classified as paired or males (Figure 5D), according to Smithers and Terry [72]. Percentage reduction in worm burden after treatment was calculated according to the following equation:

% reduction = C − V/C × 100

where C = the mean number of worms recovered from infected, untreated animals and V = the mean number of worms recovered from treated animals.

3.11.2. Number of Eggs in Liver and Intestinal Tissues

Liver and intestinal tissues were individually processed using the KOH digestion technique (Figure 5E) [73]. Egg counts were expressed as the number of eggs per gram of tissue, and the percentage reduction were calculated.

3.11.3. Oviposition Pattern

Samples from the mid-small intestine (3 cm) were collected to assess developmental stages of S. mansoni eggs (Figure 5F), as described by Pellegrino et al. [74]. The tissue was sectioned longitudinally, washed in sterile saline solution, gently dried with filter paper, and subsequently mounted between a slide and coverslip to obtain thin preparations. The slides were examined under an optical microscope for classification and percentage quantification of egg developmental stages: immature (stages I, II, III, and IV), mature, or dead.

3.12. Statistical Analysis

GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis. Results were expressed as mean ± standard deviation (SD). Analysis of variance (ANOVA) was used to compare the different experimental groups. When ANOVA revealed a significant difference, the Bonferroni post hoc test was used to identify the difference between the groups. Differences were considered significant when p < 0.05.

4. Conclusions

In the search for novel antischistosomal drugs, in vitro preclinical screening followed by in vivo evaluation is essential to determine the biological potential and safety of candidate compounds, thereby reducing time, effort, and costs prior to more complex experimental stages. Our findings reinforce the relevance of thiazole derivates as promising schistosomicidal agents.

In vitro, PBT compounds induced rapid and complete mortality, as well as pronounced motility alterations in schistosomula and juvenile worms at low concentrations, within short exposure times, and with high selectivity indices, without inducing significant cytotoxicity in mammalian cells. In vivo, treatment with PBT compounds resulted in marked reductions in total and female worm burdens, the number of eggs per gram of feces and egg deposition in hepatic and intestinal tissues, in addition to significantly altering the oviposition pattern by increasing the proportion of dead eggs.

Although the evaluated compounds exhibit low aqueous solubility and limited oral absorption, the results obtained herein provide a strong rationale for the development of pharmaceutical delivery aimed at improving their pharmacokinetic and pharmacodynamic profiles. Such strategies may enhance the antiparasitic efficacy of these compounds against S. mansoni and further strengthen their translational potential as candidates for the development of new schistosomicidal therapies.

Author Contributions

Conceptualization, A.d.L.A., M.d.C.A.d.L., H.D.A.d.A. and I.J.d.C.F.; methodology, J.V.R.d.R., I.J.d.C.F., P.H.d.B.N., W.W.M.F., L.A.O.C. and T.W.d.A.A., software, D.S.C.M. and M.T.V.G., validation, D.S.C.M., I.J.d.C.F. and M.T.V.G., formal analysis, W.W.M.F., T.W.d.A.A. and A.d.L.A., investigation. and A.L.M., resources, M.d.C.A.d.L. and A.d.L.A.; data curation,, W.W.M.F. and A.L.M.; writing—original draft preparation, A.d.L.A., J.V.R.d.R. and W.W.M.F.; writing—review and editing, A.d.L.A., W.W.M.F. and L.A.O.C.; visualization, L.A.O.C. and T.W.d.A.A.; supervision, A.d.L.A. and H.D.A.d.A.; project administration, I.J.d.C.F. and H.D.A.d.A.; funding acquisition, M.d.C.A.d.L. and A.d.L.A. All authors have read and agreed to the published version of the manuscript.

Funding

The present study was supported by the following Brazilian agencies: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, MCTI/FNDCT Nº 44/2024, Processo: 409302/2025-2, ALA), the Coordenação de Aperfeiçoamentode Pessoal de Nível Superior (CAPES n°001) and the Fundação de Amparo a Ciência e Tecnologia do Estado de Pernambuco (FACEPE). H.A.DA and JVRR would like to thank FACEPE for the Scientific and Regional Development Grant (Process DCR-0015_4.03/23) and Postgraduate Scholarships (IBPG 1832 4.01/22). In addition, H.D.A.A and A.L.A would like to thank FACEPE Research Project (Process APQ-0037_4.03/23 and APQ-Emergent 1181-4.03/22).

Institutional Review Board Statement

All experimental procedures involving animals were conducted in accordance with the guidelines of the National Council for the Control of Animal Experimentation (CONCEA) and approved by the Ethics Committee on Animal Experimentation (CEUA) of the Center for Biosciences of the Federal University of Pernambuco (UFPE), Brazil, (protocol code 0085/2022 (30 August 2022) and protocol code 0029/2025 (3 December 2025)).

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Acknowledgments

We thank the Federal University of Pernambuco (UFPE) and the Pro-Rectories of Postgraduate Studies and Research and Innovation, FACEPE, CNPq.

Conflicts of Interest

The authors declare no conflicts of interest.

References

Buonfrate, D.; Ferrari, T.C.A.; Adegnika, A.A.; Russell, S.J.; Gobbi, F.G. Human schistosomiasis. Lancet 2025, 405, 658–670. [Google Scholar] [CrossRef]
World Health Organization (WHO). Schistosomiasis. Available online: https://www.who.int/news-room/fact-sheets/detail/schistosomiasis (accessed on 24 January 2025).
Nascimento, G.L.; Pegado, H.M.; Domingues, A.L.C.; Ximenes, R.A.A.; Itria, A.; Cruz, L.N.; Oliveira, M.R.F. The cost of a disease targeted for elimination in Brazil: The case of schistosomiasis mansoni. Mem. Inst. Oswaldo Cruz 2019, 114, e180347. [Google Scholar] [CrossRef]
Ferraz, L.R.M.; Silva, L.C.P.B.B.; Souza, M.L.; Alves, L.P.; Sales, V.A.W.; Barbosa, I.D.N.G.; Andrade, M.C.; Santos, W.M.D.; Rolim, L.A.; Rolim-Neto, P.J. Drug associations as alternative and complementary therapy for neglected tropical diseases. Acta Trop. 2022, 225, 106210. [Google Scholar] [CrossRef]
Perera, D.J.; Koger-Pease, C.; Paulini, K.; Daoudi, M.; Ndao, M. Beyond schistosomiasis: Unraveling co-infections and altered immunity. Clin. Microbiol. Rev. 2024, 37, e00098-23. [Google Scholar] [CrossRef] [PubMed]
World Health Organization. Ending the Neglect to Attain the Sustainable Development Goals: A Road Map for Neglected Tropical Diseases 2021–2030; WHO: Geneva, Switzerland, 2020.
McManus, D.P.; Dunne, D.W.; Sacko, M.; Utzinger, J.; Vennervald, B.J.; Zhou, X.N. Schistosomiasis. Nat. Rev. Dis. Primers 2018, 4, 13. [Google Scholar] [CrossRef] [PubMed]
Houlder, E.L.; da Silva, L.F.; van Diepen, A.; Amaral, M.S.; Wilson, R.A.; Hokke, C.H.; Roestenberg, M.; Bakker, W.A.M. Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review. PLoS Negl. Trop. Dis. 2025, 19, e0012956. [Google Scholar] [CrossRef]
Vale, N.; Gouveia, M.J.; Rinaldi, G.; Brindley, P.J.; Gärtner, F.; Correia da Costa, J.M. Praziquantel for schistosomiasis: Single-drug metabolism revisited, mode of action, and resistance. Antimicrob. Agents Chemother. 2017, 61, e02582-16. [Google Scholar] [CrossRef]
Silva, D.V.S.P.; Nascimento, P.H.B.; Rocha, J.V.R.; Marques, D.S.C.; Brayner, F.A.; Alves, L.C.; Araújo, H.D.A.; Cruz Filho, I.J.; Albuquerque, M.C.P.A.; Lima, M.C.A.; et al. In Vitro activity, ultrastructural analysis and in silico pharmacokinetic properties (ADMET) of thiazole compounds against adult worms of Schistosoma mansoni. Acta Trop. 2023, 245, 106965. [Google Scholar] [CrossRef]
Amorim, C.R.; Pavani, T.F.A.; Lopes, A.F.S.; Duque, M.D.; Mengarda, A.C.A.; Silva, M.P.; de Moraes, J.; Rando, D.G.G. Schiff bases of 4-Phenyl-2-Aminothiazoles as hits to new antischistosomals: Synthesis, in vitro, in vivo and in silico studies. Eur. J. Pharm. Sci. 2020, 150, 105371. [Google Scholar] [CrossRef]
Niu, Z.X.; Wang, Y.T.; Zhang, S.N.; Li, Y.; Chen, X.B.; Wang, S.Q.; Liu, H.M. Application and synthesis of thiazole ring in clinically approved drugs. Eur. J. Med. Chem. 2023, 250, 115172. [Google Scholar] [CrossRef]
Haroon, M.; Akhtar, T.; Mehmood, H.; Silva, S.A.C.; da Conceição, J.M.; Brondani, G.L.; Silva Tibúrcio, R.D.; Galindo Bedor, D.C.; Viturino da Silva, J.W.; Sales Junior, P.A.; et al. Synthesis of hydrazinyl-thiazole ester derivatives, in vitro trypanocidal and leishmanicidal activities. Future Med. Chem. 2024, 16, 221–238. [Google Scholar] [CrossRef]
Alateeq, A.M.; Al-Faiyz, Y.S.; McNair, O.D.; Wiggins, J.S.; Sayed, A.R. Synthesis, Reaction and Biological Activity of Thiazoles. Curr. Org. Synth. 2025, 22, 481–515. [Google Scholar] [CrossRef]
Siddiqui, N.; Arshad, M.F.; Ahsan, W.; Alam, M.S. Thiazoles: A Valuable Insight into the Recent Advances and Biological Activities. Int. J. Pharm. Sci. Drug Res. 2009, 1, 136–143. [Google Scholar] [CrossRef]
Mohareb, R.M.; Abdallah, A.E.M.; Ahmed, E.A. Synthesis and cytotoxicity evaluation of thiazole derivatives obtained from 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile. Acta Pharm. 2017, 67, 495–510. [Google Scholar] [CrossRef]
Kubba, A.A.R.M.; Abbas, S.S. Synthesis and antimicrobial evaluation of newderivatives derived from-2 amino-4-(4-nitro-/4-bromo-phenyl thiazole). Res. J. Pharm. Biol. Chem. Sci. 2018, 9, 235–242. [Google Scholar]
Ouf, S.A.; Gomha, S.M.; Ewies, M.M.; Sharawy, I.A.A. Synthesis, Characterization, and Antifungal Activity Evaluation of Some Novel Arylazothiazoles. J. Heterocycl. Chem. 2017, 55, 258–264. [Google Scholar] [CrossRef]
Marc, G.; Stana, A.; Franchini, A.H.; Vodnar, D.C.; Barta, G.; Tertiş, M.; Şanta, I.; Cristea, C.; Pîrnău, A.; Ciorîţă, A.; et al. Phenolic Thiazoles with Antioxidant and Antiradical Activity. Synthesis, In Vitro Evaluation, Toxicity, Electrochemical Behavior, Quantum Studies and Antimicrobial Screening. Antioxidants 2021, 10, 1707. [Google Scholar] [CrossRef] [PubMed]
Saini, H.; Mehra, A.; Mittal, A. Thiazole derivatives in cancer therapy: Mechanistic insights, bioactivity, and future perspective. Future Med. Chem. 2025, 17, 2021–2042. [Google Scholar] [CrossRef] [PubMed]
Zhong, Y.; Liu, H.; Chen, F.; He, Q.; Zhang, X.; Lan, L.; Yang, C. Design, synthesis and biological evaluation of thiazolyl-halogenated pyrroles or pyrazoles as novel antibacterial and antibiofilm agents. Eur. J. Med. Chem. 2024, 268, 116221. [Google Scholar] [CrossRef]
Kumar, A.; Debnath, U.; Roy, K.K. Thiazole scaffold-based anti-tubercular agents: A review on synthesis and structural modifications. Synlett 2025, 36, 2705–2731. [Google Scholar] [CrossRef]
Cristovão-Silva, A.C.; Brelaz-de-Castro, M.C.A.; Silva, E.D.; Leite, A.C.L.; Santiago, L.B.A.A.; Conceição, J.M.; Tiburcio, R.S.; Santana, D.P.; Bedor, D.C.G.; Carvalho, B.Í.V.; et al. Trypanosoma cruzi killing and immune response boosting by novel phenoxyhydrazine-thiazole against Chagas disease. Exp. Parasitol. 2024, 261, 108749. [Google Scholar] [CrossRef]
Silva, V.G.M.; Sousa, L.M.S.; Fernandes Júnior, E.L.; Brondani, G.L.; Oliveira, I.M.A.; Bedor, D.C.G.; Lopes, I.B.P.; Brayner, F.A.; Alves, L.C.; Cavalcante, M.K.; et al. New series of 3-pyridyl-1,3-thiazoles: In Vitro and in vivo anti-Trypanosomatidae profile, in vitro and in silico mechanism of action approach. Eur. J. Med. Chem. 2025, 284, 117191. [Google Scholar] [CrossRef]
Rosada, B.; Bekier, A.; Cytarska, J.; Płaziński, W.; Zavyalova, O.; Sikora, A.; Dzitko, K.; Łączkowski, K. Benzo[b]thiophene-thiazoles as potent anti-Toxoplasma gondii agents: Design, synthesis, tyrosinase/tyrosine hydroxylase inhibitors, molecular docking study, and antioxidant activity. Eur. J. Med. Chem. 2019, 184, 111765. [Google Scholar] [CrossRef]
Almutairi, T.; Rezki, N.; Aouad, M.; Hagar, M.; Bakr, B.; Tarek, M.; Khairy, M.; Elwakil, B.; Moneer, E. Exploring the antiparasitic activity of tris-1,3,4-thiadiazoles against Toxoplasma gondii-infected mice. Molecules 2022, 27, 2246. [Google Scholar] [CrossRef]
Kalita, T.; Choudhury, A.; Shakya, A.; Ghosh, S.K.; Singh, U.P.; Bhat, H.R. A Review on Synthetic Thiazole Derivatives as an Antimalarial Agent. Curr. Drug Discov. Technol. 2024, 21, e240124226141. [Google Scholar] [CrossRef]
Nava-Zuazo, C.; Chávez-Silva, F.; Moo-Puc, R.; Chan-Bacab, M.J.; Ortega-Morales, B.O.; Moreno-Díaz, H.; Díaz-Coutiño, D.; Hernández-Núñez, E.; Navarrete-Vázquez, G. 2-Acylamino-5-nitro-1,3-thiazoles: Preparation and in vitro bioevaluation against four neglected protozoan parasites. Bioorg. Med. Chem. 2014, 22, 1626–1633. [Google Scholar] [CrossRef] [PubMed]
Vajedpour, M.; Shiran, J.A.; Ashnamoghadam, A.; Kaboudin, B.; Razzaghi-Asl, N. Structural perspective into thiazoles and other azole derivatives as anthelmintic agents. Acta Trop. 2024, 260, 107463. [Google Scholar] [CrossRef] [PubMed]
Rocha, R.E.T.; Almeida Júnior, A.S.A.; Júnior, N.C.P.; Nascimento, A.V.; Leite, N.M.S.; Oliveira, J.F.; Alves de Lima, M.D.C.; Feitosa, A.P.S.; Bezerra de Mélo, M.E.; Brayner, F.A.; et al. Synthesis, in vitro schistosomicidal activity and ultrastructural alterations caused by thiosemicarbazones and thiazolidinones against juvenile and adult Schistosoma mansoni worms (Sambon, 1907). Mol. Biochem. Parasitol. 2022, 252, 111520. [Google Scholar] [CrossRef]
da Silva Rangel, L.; Gonzaga, D.T.G.; da Silva, A.C.R.; von Ranke, N.L.; Rodrigues, C.R.; Santos, J.A.A.D.; Boechat, N.; Gomes, K.N.F.; Teixeira, G.P.; Faria, R.X. Molluscicidal and Schistosomicidal Activities of 2-(1H-Pyrazol-1-yl)-1,3,4-thiadiazole Derivatives. Pharmaceuticals 2025, 18, 429. [Google Scholar] [CrossRef]
Pereira, A.S.A.; Silveira, G.O.; Amaral, M.S.; Almeida, S.M.V.; Oliveira, J.F.; Lima, M.C.A.; Verjovski-Almeida, S. In Vitro activity of aryl-thiazole derivatives against Schistosoma mansoni schistosomula and adult worms. PLoS ONE 2019, 14, e0225425. [Google Scholar] [CrossRef]
Santiago, E.F.; Oliveira, S.A.; Oliveira-Filho, G.B.; Moreira, D.R.; Gomes, P.A.; Silva, A.L.; Barros, A.F.; Silva, A.C.; Santos, T.A.; Pereira, V.R.; et al. Evaluation of the anti-Schistosoma mansoni activity of thiosemicarbazones and thiazoles. Antimicrob. Agents Chemother. 2014, 58, 352–363. [Google Scholar] [CrossRef] [PubMed]
Araújo, H.D.A.; Santos, V.H.B.; Brayner, F.A.; Alves, L.C.; Silva, N.H.; Albuquerque, M.C.P.A.; Aires, A.L.; Lima, V.L.M. In Vitro activity of usnic acid potassium salt against different developmental stages of Schistosoma mansoni: An ultrastructural study. Acta Trop. 2020, 201, 105159. [Google Scholar] [CrossRef] [PubMed]
Talaam, K.K.; Inaoka, D.K.; Hatta, T.; Tsubokawa, D.; Tsuji, N.; Wada, M.; Saimoto, H.; Kita, K.; Hamano, S. Mitochondria as a Potential Target for the Development of Prophylactic and Therapeutic Drugs against Schistosoma mansoni Infection. Antimicrob. Agents Chemother. 2021, 65, e0041821. [Google Scholar] [CrossRef]
Lorsuwannarat, N.; Saowakon, N.; Ramasoota, P.; Wanichanon, C.; Sobhon, P. The anthelmintic effect of plumbagin on Schistosoma mansoni. Exp. Parasitol. 2013, 133, 18–27. [Google Scholar] [CrossRef] [PubMed]
Debbert, S.L.; Hintz, M.J.; Bell, C.J.; Earl, K.R.; Forsythe, G.E.; Häberli, C.; Keiser, J. Activities of Quinoxaline, Nitroquinoxaline, and [1,2,4]Triazolo [4,3-a]quinoxaline Analogs of MMV007204 against Schistosoma mansoni. Antimicrob. Agents Chemother. 2021, 65, e01370-20. [Google Scholar] [CrossRef]
Padalino, G.; El-Sakkary, N.; Liu, L.J.; Liu, C.; Harte, D.S.G.; Barnes, R.E.; Sayers, E.; Forde-Thomas, J.; Whiteland, H.; Bassetto, M.; et al. Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation. Eur. J. Med. Chem. 2021, 226, 113823. [Google Scholar] [CrossRef]
de Oliveira, S.A.; de Oliveira Barbosa, M.; Filho, C.A.L.M.; Oliveira, A.R.; de Sousa, F.A.; de Farias Santiago, E.; de Oliveira Filho, G.B.; Moraes Gomes, P.A.T.; Conceição, J.M.; Brayner, F.A.; et al. Phthalimido-thiazole as privileged scaffold: Activity against immature and adult worms of Schistosoma mansoni. Parasitol. Res. 2018, 117, 2105–2115. [Google Scholar] [CrossRef]
de Oliveira Barbosa, M.; de Oliveira, S.A.; Filho, C.A.L.M.; Oliveira, A.R.; Fernandes, C.J.B.; Lucena, J.P.; de Sousa, F.A.; de Barros Dias, M.C.H.; Brayner, F.A.; Alves, L.C.; et al. Schistosomicidal and prophylactic activities of phthalimido-thiazoles derivatives on schistosomula and adult worms. Eur. J. Pharm. Sci. 2019, 133, 15–27. [Google Scholar] [CrossRef]
Yang, T.; Sui, X.; Yu, B.; Shen, Y.; Cong, H. Recent advances in the rational drug design based on multi-target ligands. Curr. Med. Chem. 2020, 27, 4720–4740. [Google Scholar] [CrossRef]
Miranda-Filho, C.A.L.; Barbosa, M.O.; Oliveira, A.R.; Santiago, E.F.; Souza, V.C.A.; Lucena, J.P.; Fernandes, C.J.B.; Santos, I.R.D.; Leão, R.L.C.; Santos, F.A.B.D.; et al. In Vitro and in vivo activities of multi-target phtalimido-thiazoles on Schistosomiasis mansoni. Eur. J. Pharm. Sci. 2020, 146, 105236. [Google Scholar] [CrossRef]
Alqahtani, A.M.; Bayazeed, A.A. Synthesis and antiproliferative activity studies of new functionalized pyridine linked thiazole derivatives. Arab. J. Chem. 2021, 14, 102914. [Google Scholar] [CrossRef]
Gali, R.; Banothu, J.; Porika, M.; Velpula, R.; Bavantula, R.; Abbagani, S. Synthesis and in vitro cytotoxic activity of novel coumarinylimidazo[2,1-b]thiazole derivatives. RSC Adv. 2014, 4, 53812–53819. [Google Scholar] [CrossRef]
Wei, F.; Wang, S.; Gou, X. A review for cell-based screening methods in drug discovery. Biophys. Rep. 2021, 7, 504–516. [Google Scholar] [CrossRef]
de Sá, N.P.; Lino, C.I.; Fonseca, N.C.; Borelli, B.M.; Ramos, J.P.; Souza-Fagundes, E.M.; Rosa, C.A.; Santos, D.A.; de Oliveira, R.B.; Johann, S. Thiazole compounds with activity against Cryptococcus gattii and Cryptococcus neoformans in vitro. Eur. J. Pharm. Sci. 2015, 102, 233–242. [Google Scholar] [CrossRef]
Aliança, A.S.D.S.; Oliveira, A.R.; Feitosa, A.P.S.; Ribeiro, K.R.C.; Castro, M.C.A.B.; Leite, A.C.L.; Alves, L.C.; Brayner, F.A. In Vitro evaluation of cytotoxicity and leishmanicidal activity of phthalimido-thiazole derivatives. Eur. J. Pharm. Sci. 2017, 105, 1–10. [Google Scholar] [CrossRef]
Vaillant, M.T.; Philippy, F.; Neven, A.; Barré, J.; Bulaev, D.; Olliaro, P.L.; Utzinger, J.; Keiser, J.; Garba, A.T. Diagnostic tests for human Schistosoma mansoni and Schistosoma haematobium infection: A systematic review and meta-analysis. Lancet Microbe 2024, 5, e366–e378. [Google Scholar] [CrossRef]
Díaz, A.V.; Walker, M.; Webster, J.P. Reaching the World Health Organization elimination targets for schistosomiasis: The importance of a One Health perspective. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2023, 378, 20220274. [Google Scholar] [CrossRef]
Cruz, C.S.; França, W.W.M.; Arújo, H.D.A.; Ximenes, E.C.P.A.; Souza, V.M.; Albuquerque, M.C.P.A.; Aires, A.L.; Costa, V.M.A. In Vitro and in vivo evaluation of Bacillus clausii against Schistosoma mansoni. Acta Trop. 2022, 235, 106669. [Google Scholar] [CrossRef]
Aires, A.L.; Araújo, H.D.A.; Galvão, A.M.; Araújo, S.B.; Silva, R.L.; Anjos, Z.P.; Souza, M.M.B.; Souza, V.M.O.; Azevedo, A.M.C.P. Schistosomicidal, hepatoprotective and antioxidant activities of the N-acetyl-L-cysteine and/or praziquantel in experimental acute mansonic schistosomiasis. 3 Biotech 2023, 13, 215. [Google Scholar] [CrossRef]
Silva, L.M.N.; França, W.W.M.; Santos, V.H.B.; Souza, R.A.F.; Silva, A.M.; Diniz, E.G.M.; Aguiar, T.W.A.; Rocha, J.V.R.; Souza, M.A.A.; Nascimento, W.R.C.; et al. Plumbagin: A Promising In Vivo Antiparasitic Candidate against Schistosoma mansoni and In Silico Pharmacokinetic Properties (ADMET). Biomedicines 2023, 11, 2340. [Google Scholar] [CrossRef] [PubMed]
Lamberton, P.H.; Faust, C.L.; Webster, J.P. Praziquantel decreases fecundity in Schistosoma mansoni adult worms that survive treatment: Evidence from a laboratory life-history trade-offs selection study. Infect. Dis. Poverty 2017, 6, 110. [Google Scholar] [CrossRef] [PubMed]
Wang, N.; Peng, H.Q.; Gao, C.Z.; Cheng, Y.H.; Sun, M.T.; Qu, G.L.; Webster, J.P.; Lu, D.B. In Vivo efficiency of praziquantel treatment of single-sex Schistosoma japonicum aged three months old in mice. Int. J. Parasitol. Drugs Drug Resist. 2022, 20, 129–134. [Google Scholar] [CrossRef]
Tavares, N.C.; Mourão, M.M. Parasitemia Evaluation in Mice Infected with Schistosoma mansoni. Bio-Protocol 2021, 11, e4017. [Google Scholar] [CrossRef]
Paula, F.R.; Serrano, S.H.P.; Tavares, L.C. Aspects of Bioactivity and Toxicity of Nitrocompounds. Quim. Nova. 2009, 32, 1013–1020. [Google Scholar] [CrossRef]
Noriega, S.; Cardoso-Ortiz, J.; López-Luna, A.; Cuevas-Flores, M.D.R.; Flores, T.J.A. The Diverse Biological Activity of Recently Synthesized Nitro Compounds. Pharmaceuticals 2022, 15, 717. [Google Scholar] [CrossRef]
Zhang, J.; Gulyás, K.V.; Li, J.; Ma, M.; Zhou, L.; Wu, L.; Xiong, R.; Erdelyi, M.; Zhu, W.; Xu, Z. Unexpected effect of halogenation on the water solubility of small organic compounds. Comput. Biol. Med. 2024, 172, 108209. [Google Scholar] [CrossRef]
Mallappa; Chahar, M.; Choudhary, N.; Yadav, K.K.; Qasim, M.T.; Zairov, R.; Patel, A.; Yadav, V.K.; Jangir, M. Recent advances in the synthesis of nitrogen-containing heterocyclic compounds via multicomponent reaction and their emerging biological applications: A review. J. Iran. Chem. Soc. 2024, 22, 1–33. [Google Scholar] [CrossRef]
Liu, B.; Gordon, W.P.; Richmond, W.; Groessl, T.; Tuntland, T. Use of solubilizers in preclinical formulations: Effect of Cremophor EL on the pharmacokinetic properties on early discovery compounds. Eur. J. Pharm. Sci. 2016, 87, 52–57. [Google Scholar] [CrossRef]
Oliveira, J.F.; Silva, A.L.; Vendramini-Costa, D.B.; Amorim, C.A.C.; Campos, J.F.; Ribeiro, A.G.; Olímpio de Moura, R.; Neves, J.L.; Ruiz, A.L.; Ernesto de Carvalho, J.; et al. Synthesis of thiophene-thiosemicarbazone derivatives and evaluation of their in vitro and in vivo antitumor activities. Eur. J. Med. Chem. 2015, 104, 148–156. [Google Scholar] [CrossRef] [PubMed]
Oliveira Filho, G.B.; Cardoso, M.V.O.; Espíndola, J.W.P.; Oliveira, S.D.A.; Ferreira, R.S.; Coelho, P.L.; Anjos, P.S.D.; Santos, E.S.; Meira, C.S.; Moreira, D.R.M.; et al. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi. Eur. J. Med. Chem. 2017, 141, 346–361. [Google Scholar] [CrossRef] [PubMed]
Alves, J.E.F.; Oliveira, J.F.; Souza, T.R.C.L.; Moura, R.O.; Júnior, L.B.C.; Lima, M.C.A.; Almeida, S.M.V. Novel indole-thiazole and indole-thiazolidinone derivatives as DNA groove binders. Int. J. Biol. Macromol. 2021, 170, 622–635. [Google Scholar] [CrossRef] [PubMed]
Hoffman, W.A.; Pons, J.A.; Janer, J.L. The sedimentation-concentration method in schistosomiasis mansoni. Puerto Rico J. Public Health Trop. Med. 1934, 9, 281–298. [Google Scholar]
Ramalho-Pinto, F.J.; Gazzinelli, G.; Howells, R.E.; Montastrucq, E.; Pellegrino, J. Defined conditions for the transformation of Schistosoma mansoni cercariae into schistosomula in vitro. Exp. Parasitol. 1974, 36, 360–372. [Google Scholar] [CrossRef]
Smithers, S.R.; Terry, R.J. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of adult worms. Parasitology 1965, 55, 695–700. [Google Scholar] [CrossRef]
Aires, A.L.; Ximenes, E.C.; Silva, R.A.; Barbosa, V.X.; Góes, A.J.; Peixoto, C.A.; Souza, V.M.; Albuquerque, M.C. Ultrastructural analysis of β-lapachone-induced surface membrane damage in male adult Schistosoma mansoni BH strain worms. Exp. Parasitol. 2014, 142, 83–90. [Google Scholar] [CrossRef]
Araújo, H.D.A.; Aires, A.L.; Soares, C.L.R.; Brito, T.G.S.; Nascimento, W.M.; Martins, M.C.B.; Silva, T.G.; Brayner, F.A.; Alves, L.C.; Silva, N.H.; et al. Usnic acid potassium salt from Cladonia substellata (Lichen): Synthesis, cytotoxicity and in vitro anthelmintic activity and ultrastructural analysis against adult worms of Schistosoma mansoni. Acta Trop. 2019, 192, 1–10. [Google Scholar] [CrossRef]
Layoun, A.; Samba, M.; Santos, M.M. Isolation of murine peritoneal macrophages to carry out gene expression analysis upon Toll-like receptors stimulation. J. Vis. Exp. JoVE 2015, 98, e52749. [Google Scholar] [CrossRef]
Zhang, X.; Gonçalves, R.; Mosser, D.M. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. 2008, 83, 14.1.1–14.1.14. [Google Scholar] [CrossRef]
Carvalho, L.V.; Cordeiro, M.F.; Lins, T.U.; Sampaio, M.C.; Mello, G.S.; Costa, V.C.; Marques, L.L.; Klein, T.; Mello, J.C.; Cavalcanti, I.M.; et al. Evaluation of Antibacterial, Antineoplastic, and Immunomodulatory Activity of Paullinia cupana Seeds Crude Extract and Ethyl-Acetate Fraction. Evid. Based Complement. Alternat Med. 2016, 2016, 1203274. [Google Scholar] [CrossRef]
Olivier, L.; Stirewalt, M.A. An Efficient Method for Exposure of Mice to Cercariae of Schistosoma mansoni. J. Parasitol. 1952, 38, 19–23. [Google Scholar] [CrossRef]
Cheever, A.W. Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. Bull. World Health Organ. 1968, 39, 328–331. [Google Scholar] [PubMed]
Pellegrino, J.; Oliveira, C.A.; Faria, J.; Cunha, A.S. New approach to the screening of drugs in experimental schistosomiasis mansoni in mice. Am. J. Trop. Med. Hyg. 1962, 11, 201–215. [Google Scholar] [CrossRef] [PubMed]

Figure 1. In vitro effect of thiazole compounds (PBT2, PBT5 and PBT6) on the cell viability of Schistosoma mansoni schistosomula (A) and young worms (B). Positive controls were treated with praziquantel (PQZ, 10 μM). Viability was expressed as mean ± SD in percentage viability. ^a p < 0.001 compared to the negative control (C2). ^b p < 0.001 compared to the positive control PZQ. Control 1 (C1): supplemented RPMI. Control 2 (C2): RPMI supplemented with 1.0% DMSO.

Figure 2. Effect of thiazole compounds (PBT2, PBT5, and PBT6) and praziquantel (PZQ) on fecal egg counts (EPG) in S. mansoni-infected mice. Data are presented as mean ± SD. ^a p < 0.001 versus negative controls (C1 and C2). The positive control worms were treated with praziquantel (PQZ, 10 μM).

Figure 3. Thiazole compounds synthesis scheme.

Figure 4. Methodological scheme of in vitro studies. (A) Mechanical transformation of cercariae into Schistosoma mansoni schistosomes; (B) Perfusion of the hepatic portal system for recovery of young worms; (C) Plating and incubation (24 h, 37 °C, 5% CO₂) of schistosomes and young worms with PBT2, PBT5 and PBT6 compounds; (D) Visualization by inverted microscope for evaluation of motility and mortality scores; and (E) Evaluation of the cytotoxicity of schistosomes and young worms after incubation with the compounds. Created in BioRender. França, W.W.M. (2026), accessed on 1 February 2026. https://BioRender.com/pcecbz5.

Figure 5. Methodological scheme of in vivo studies. (A) Exposure of Biomphalaria glabrata for shedding of Schistosoma mansoni cercariae; (B) Percutaneous infection of mice with S. mansoni cercariae; (C) Oral administration of PBT2, PBT5, or PBT6 compounds; (D) Perfusion of the hepatic portal system and mesenteric vessels for recovery of adult S. mansoni worms; (E) Digestion of hepatic and intestinal tissue in KOH for quantification of eggs in the tissues; and (F) Oogram method for evaluating the oviposition pattern. Created in BioRender. França, W.W.M. (2026), accessed on 1 February 2026. https://BioRender.com/d0nc0j5.

Table 1. Motility scores of schistosomula, treated with praziquantel (PZQ) or thiazole compounds (PBT2, PBT5, or PBT6) after 3, 6, 12, and 24 h of incubation.

Experimental Groups	Mean ± Standard Deviation and Percentage (%) of Young Worms in Motility Scores After Incubation
	3 h			6 h			12 h			24 h
	0	1.5	3	0	1.5	3	0	1.5	3	0	1.5	3
Control 1			70 ± 0.0 (100 %)			70 ± 0.0 (100 %)			70 ± 0.0 (100 %)			70 ± 0.0 (100 %)
Control 2			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
PZQ
10 µM		70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
PBT2
200 μM	70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
100 μM	70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
50 μM		70 ± 0.0 (100%)		56 ± 8.0 (82.9%)	14 ± 3.0 (17.1%)		70 ± 0.0 (100%)			70 ± 0.0 (100%)
25 μM			70 ± 0.0 (100%)		33 ± 3.5 (47.2%)	37 ± 2.0 (52.8%)		70 ± 0.0 (100%)		70 ± 0.0 (100%)
12.5 μM			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)		50 ± 0.0 (71.4%)
6.25 μM			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
PBT5
200 μM	70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
100 μM	70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
50 μM		35 ± 0.0 (50%)	35 ± 0.0 (50%)		70 ± 0.0 (100%)		70 ± 0.0 (100%)			70 ± 0.0 (100%)
25 μM			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)		70 ± 0.0 (100%)
12.5 μM			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)		70 ± 0.0 (100%)
6.25 μM			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
PBT6
200 μM	70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
100 μM	70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
50 μM		48 ± 0.0 (58.6%)	22 ± 0.0 (31.4%)	70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)
25 μM			70 ± 0.0 (100%)		18 ± 2.0 (25.7%)	52 ± 5.0 (74.3%)	70 ± 0.0 (100%)			70 ± 0.0 (100%)
12.5 μM			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)		55 ± 0.0 (78.6%)	15 ± 0.0 (21.4%)
6.25 μM			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)			70 ± 0.0 (100%)

Control 1: Schistosomula incubated only in supplemented RPMI. Control 2: Schistosomula incubated in RPMI supplemented with 1.0% DMSO. Score 3: Typical movements along the body; peristalsis of internal organs and suckers adhered to the sides and bottom of the culture plate. Score 1.5: Movement only in the extremities (posterior and/or anterior). Score 0: Complete absence of movements and tegument with or without color change.

Table 2. Motility scores of young worms treated with praziquantel (PZQ) or thiazole compounds (PBT2, PBT5, or PBT6) after 3, 6, 12, and 24 h of incubation.

Experimental Groups	Mean ± Standard Deviation (SD) and Percentage (%) of Young Worms in Motility Scores After Incubation
	3 h				6 h				12 h				24 h
	0	1	2	3	0	1	2	3	0	1	2	3	0	1	2	3
Control 1				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
Control 2				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
PZQ
10 µM		30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
PBT2
200 µM	30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
100 µM	30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
50 µM		18 ± 4.0 (60%)	12 ± 3.0 (40%)			27 ± 2.5 (90%)	3 ± 0.0 (10%)			30 ± 0.0 (100%)			30 ± 0.0 (100%)
25 µM				30 ± 0.0 (100%)			21 ± 2.0 (70%)	9 ± 2.0 (30%)			30 ± 0.0 (100%)				30 ± 0.0 (100%)
12.5 µM				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
6.25 µM				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
PBT5
200 µM	30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
100 µM	30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
50 µM			24 ± 4.0 (80%)	6 ± 1.0 (20%)			30 ± 0.0 (100%)			19 ± 3.5 (66.33%)	11 ± 2.0 (36.66%)		30 ± 0.0 (100%)
25 µM				30 ± 0.0 (100%)				30 ± 0.0 (100%)								30 ± 0.0 (100%)
12.5 µM				30 ± 0.0 (100%)				30 ± 0.0 (100%)								30 ± 0.0 (100%)
6.25 µM				30 ± 0.0 (100%)				30 ± 0.0 (100%)								30 ± 0.0 (100%)
PBT6
200 µM	30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
100 µM	30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
50 µM		30 ± 0.0 (100%)			30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
25 µM				30 ± 0.0 (100%)			30 ± 0.0 (100%)			15 ± 0.0 (50%)	15 ± 0.0 (50%)			30 ± 0.0 (100%)
12.5 µM				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)
6.25 µM				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)				30 ± 0.0 (100%)

Control 1: Young worms incubated only in supplemented RPMI. Control 2: Young worms incubated in RPMI supplemented with 1.0% DMSO. Score 3: Typical movements along the body; peristalsis of internal organs and suckers adhered to the sides and bottom of the culture plate. Score 2: Reduced movements along the body and reduced peristalsis. Score 1: Movement only in the extremities (posterior and/or anterior). Score 0: Complete absence of movements and tegument with or without color change.

Table 3. Cytotoxicity (CC₅₀: inhibits cell growth by 50%), lethal concentration antiparasitic (CL₅₀: 50% lethality of worms) and selectivity index (SI) promoted by thiazole compounds (PBT2, PBT5, and PBT6).

Compounds	Splenocytes CC₅₀ (μM)	Peritoneal Macrophages CC₅₀ (μM)	S. masoni (CL₅₀ μM)		SI Splenocytes		SI Peritoneal Macrophages
Compounds	Splenocytes CC₅₀ (μM)	Peritoneal Macrophages CC₅₀ (μM)	Schistosomes	Young	Schistosomes	Young	Schistosomes	Young
PBT2	193.9 ± 8.4	277.5 ± 11.6	27.84 ± 3.4	32.85 ± 3.8	6.96	5.9	9.96	8.44
PBT5	204.2 ± 12.6	281.9 ± 9.4	30.89 ± 2.8	34.92 ± 3.2	6.61	5.84	9.12	8.07
PBT6	297.3 ± 15.8	>400	15.33 ± 2.2	27.76 ± 2.5	19.39	10.7	>26	>14.4
PZQ	3.2 ± 0.8	>400	>10	>10	<0.32	<0.32	>40	>40

Note: Results expressed as mean ± standard deviation.

Table 4. Effects of thiazole compounds (PBT2, PBT5, or PBT6) and praziquantel (PZQ) on the parasite load of worms (total and females) and eggs in the liver and intestinal tissues of mice infected with S. mansoni, euthanized 55 days after infection.

Groups	Average Worm Burden				Number of Eggs/g Tissue × 10³
Groups	Total	Reduction (%)	Female	Reduction (%)	Hepatic	Reduction (%)	Intestinal	Reduction (%)
Control 1	59.89 ± 6.9	-	27.9 ± 3.9	-	7.12 ± 0.87	-	11.58 ± 0.66	-
Control 2	61.45 ± 6.17	-	28.3 ± 4.08	-	7.45 ± 1.22	-	12.16 ± 2.11	-
PZQ
50 mg/kg	0.55 ± 0.73	99.08	0.44 ± 0.53	98.42	0.88 ± 0.85	87.64	2.11 ± 0.49	81.78
PBT2
200 mg/kg	22.57 ± 6.92 ***	62.31	11.86 ± 2.41 ***	57.49	3.86 ± 0.73 ***	45.79	4.9 ± 0.14 ***^,e	57.68
100 mg/kg	32.67 ± 11.81 ***	45.44	15.17 ± 6.05 ***	45.62	4.11 ± 0.81 ***	42.28	7.11 ± 0.52 ***^,a	38.6
50 mg/kg	36.14 ± 5.52 ***^,a	39.65	16.13 ± 2.75 ***	42.18	4.53 ± 0.74 ***	36.38	6.92 ± 0.45 ***^,a	40.24
PBT5
200 mg/kg	22.86 ± 4.59 ***	61.83	9.71 ± 2.21 ***	65.19	2.89 ± 0.47 ***	59.41	4.46 ± 0.39 ***	61.5
100 mg/kg	25.29 ± 6.18 ***	57.77	12.14 ± 2.61 ***	56.48	3.15 ± 0.38 ***^,b	55.75	5.28 ± 0.7 ***^,b	54.4
50 mg/kg	53.14 ± 8.95 ***^,b	11.27	25.57 ± 5.06 ^b	8.35	6.5 ± 0.54 ^b	8.7	10.7 ± 0.1 ^b	7.6
PBT6
200 mg/kg	20.57 ± 6.82 ***	65.65	12.0 ± 3.1 ***^,	56.98	3.89 ± 0.75 ***	45.4	5.1 ± 0.79 ***	55.96
100 mg/kg	33.14 ± 6.74 ***^,c	44.66	19.50 ± 3.6 ***^,c	30.11	4.67 ± 0.61 ***	34.41	8.15 ± 0.74 ***^,d	29.62
50 mg/kg	37.83 ± 3.25 ***^,d	36.83	18.29 ± 2.81 ***^,d	34.44	4.41 ± 0.43 ***^,c	38.06	8.2 ± 0.11 ***^,d	29.2

Control 1 = infected animals that only sterile saline solution. Control 2 = infected animals that received 1% Cremophor^® in sterile saline solution. *** p < 0.001 significant difference compared to the control1 group. ^a p < 0.01 significant difference compared to PBT2 at 200 mg/kg. ^b p < 0.001 significant difference compared to PBT5 at 200 and 100 mg/kg. ^c p < 0.01, ^d p < 0.001 significant difference compared to PBT6 at 200 mg/kg. ^e p < 0.001 significant difference compared to PBT2 at 200 and 50 mg/kg.

Table 5. Effect of thiazole compounds (PBT2, PBT5, and PBT6) and praziquantel (PZQ) on the oogram of mice infected with S. mansoni when administered from the 45th to the 49th day post-infection and euthanized on the 55th day of infection.

Groups	% of Eggs per Developmental Stage
Groups	Immature	Mature	Dead
Control 1	57.2 ± 8.52	38.0 ± 7.03	4.8 ± 1.64
Control 2	55.4 ± 6.31	39.8 ± 4.86	4.8 ± 1.92
PZQ
50 mg/kg	0.0 ± 0.0 ***	4.2 ± 0.83 ***	95.8 ± 0.83 ***
PBT2
200 mg/kg	15.4 ± 6.38 ***	28.4 ± 3.21 ***	56.2 ± 7.08 ***
100 mg/kg	27.6 ± 3.36 ***^,a	38.6 ± 4.15 ^b	33.8 ± 5.02 ***^,a
50 mg/kg	39.4 ± 5.17 ***^,b	43.8 ± 5.21 ^a	16.8 ± 3.63 ***^,a
PBT5
200 mg/kg	17.0 ± 4.0 ***	29.8 ± 4.47 ***	53.2 ± 2.16 ***
100 mg/kg	29.4 ± 3.78 ***^,b	35.8 ± 5.16	34.8 ± 6.14 ***^,a
50 mg/kg	55.4 ± 2.51 ^a	39.0 ± 2.23 ^a	5.6 ± 1.51 ^a
PBT6
200 mg/kg	18.0 ± 2.34 ***	22.6 ± 8.4 ***	59.4 ± 6.5 ***
100 mg/kg	26.4 ± 3.21 ***^,b	36.0 ± 2.55 ^a	37.6 ± 4.15 ***^,a
50 mg/kg	39.6 ± 4.72 ***^,a	37.6 ± 4.33 ^a	22.8 ± 4.65 ***^,a

Control 1 = infected animals that received only sterile saline solution. Control 2 = infected animals that received 1% Cremophor^® in sterile saline solution. *** p < 0.001 significant difference compared to the control 1 and 2 groups. ^a p < 0.001, ^b p < 0.01 significant intragroup difference with 200 mg/kg at the same developmental stage.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rocha, J.V.R.d.; França, W.W.M.; Machado, A.L.; Cavalcante, L.A.O.; Gonçalves, M.T.V.; Aguiar, T.W.d.A.; Marques, D.S.C.; Nascimento, P.H.d.B.; Araújo, H.D.A.d.; Filho, I.J.d.C.; et al. Thiazole as a Promising Scaffold for the Treatment of Schistosomiasis: In Vitro and In Vivo Activity Against Different Developmental Stages of Schistosoma mansoni. Pharmaceuticals 2026, 19, 420. https://doi.org/10.3390/ph19030420

AMA Style

Rocha JVRd, França WWM, Machado AL, Cavalcante LAO, Gonçalves MTV, Aguiar TWdA, Marques DSC, Nascimento PHdB, Araújo HDAd, Filho IJdC, et al. Thiazole as a Promising Scaffold for the Treatment of Schistosomiasis: In Vitro and In Vivo Activity Against Different Developmental Stages of Schistosoma mansoni. Pharmaceuticals. 2026; 19(3):420. https://doi.org/10.3390/ph19030420

Chicago/Turabian Style

Rocha, João Victor Ritinto da, Wilza Wanessa Melo França, Arthur Lessa Machado, Lucas Andrade Oliveira Cavalcante, Maria Tairla Viana Gonçalves, Thierry Wesley de Albuquerque Aguiar, Diego Santa Clara Marques, Pedro Henrique do Bomfim Nascimento, Hallysson Douglas Andrade de Araújo, Iranildo José da Cruz Filho, and et al. 2026. "Thiazole as a Promising Scaffold for the Treatment of Schistosomiasis: In Vitro and In Vivo Activity Against Different Developmental Stages of Schistosoma mansoni" Pharmaceuticals 19, no. 3: 420. https://doi.org/10.3390/ph19030420

APA Style

Rocha, J. V. R. d., França, W. W. M., Machado, A. L., Cavalcante, L. A. O., Gonçalves, M. T. V., Aguiar, T. W. d. A., Marques, D. S. C., Nascimento, P. H. d. B., Araújo, H. D. A. d., Filho, I. J. d. C., Lima, M. d. C. A. d., & Aires, A. d. L. (2026). Thiazole as a Promising Scaffold for the Treatment of Schistosomiasis: In Vitro and In Vivo Activity Against Different Developmental Stages of Schistosoma mansoni. Pharmaceuticals, 19(3), 420. https://doi.org/10.3390/ph19030420

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Thiazole as a Promising Scaffold for the Treatment of Schistosomiasis: In Vitro and In Vivo Activity Against Different Developmental Stages of Schistosoma mansoni

Abstract

1. Introduction

2. Results and Discussion

2.1. Thiazole Compounds Induce Mortality, Impair Motility, and Reduce Cell Viability in Schistosomula and Juvenile Worms of Schistosoma mansoni

2.2. Thiazole Compounds Significantly Reduce Cell Viability of Schistosomula and Juvenile Worms

2.3. Lethal Concentration, Cytotoxicity, and Selectivity Index

2.4. The Compounds Reduce Fecal Egg Output, Adult Worm Burden, Tissue Egg Deposition, and Alter the Oviposition Pattern in Mice Infected with Schistosoma mansoni

3. Materials and Methods

3.1. Reagents and Solvents

3.2. Synthesis of Thiazole Compounds

3.3. Ethics Committee and Animals

3.4. Infection of Biomphalaria glabrata and Collection of S. mansoni Cercariae

3.5. In Vitro Assay Against S. mansoni Schistosomula

3.6. In Vitro Assay Against Juvenile S. mansoni Worms

3.7. In Vitro Schistosomicidal Criteria Against Schistosomula and Juvenile Worms

3.7.1. Motility and Survival

3.7.2. Cell Viability Assay

3.8. Cytotoxicity Assay in Murine Peritoneal Macrophages and Splenocytes

3.9. In Vitro Selectivity Index

3.10. Experimental Infection and Therapeutic Protocol

3.11. In Vivo Parasitological Parameters

3.11.1. Adult Worm Recovery

3.11.2. Number of Eggs in Liver and Intestinal Tissues

3.11.3. Oviposition Pattern

3.12. Statistical Analysis

4. Conclusions

Author Contributions

Funding

Institutional Review Board Statement

Informed Consent Statement

Data Availability Statement

Acknowledgments

Conflicts of Interest

References

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI